Mysterious Therapy: Antineoplastons and Their Role in Cancer Treatment

Summary

Antineoplastons represent a controversial and experimental approach to cancer treatment, consisting of compounds found in human urine and blood, which have shown potential in laboratory and animal studies but lack conclusive evidence from randomized controlled human trials.

Abstract

Antineoplastons, a group of compounds originally isolated from human urine, have been proposed by S.R. Burzynski as a treatment for cancer since 1976, with the hypothesis that they function as part of a biochemical surveillance system to regulate cell differentiation. Over the years, these compounds have been synthesized in the lab for research purposes. Despite some promising results in preclinical studies, the efficacy of antineoplastons in cancer treatment remains unproven in the context of randomized controlled trials. Current research is ongoing, primarily at the Burzynski Institute, but the lack of peer-reviewed evidence and concerns about serious side effects, particularly neurological toxicity, have led to cautious attitudes towards their use. The U.S. Food and Drug Administration has not approved antineoplastons for any disease, and they should be considered only within a comprehensive treatment plan under the guidance of a qualified healthcare provider.

Opinions

The developer of antineoplastons, S.R. Burzynski, posits that these compounds can correct abnormal differentiation in cancer cells.
The theoretical basis for antineoplaston therapy includes the notion that peptides act as information carriers and control cellular information transfer and energy expenditure.
There is an emphasis on the need for more research to ascertain the effectiveness of antineoplastons, particularly through randomized controlled trials.
Concerns are raised about the potential for serious neurological side effects associated with antineoplaston treatment.
The article advises that antineoplastons should be approached with caution and only as part of a well-informed treatment plan, with the consultation of a healthcare provider.
The article suggests that the current data on antineoplastons is insufficient for their widespread adoption in cancer treatment protocols.

Mysterious Therapy: Antineoplastons and Their Role in Cancer Treatment

Antineoplastons are drugs composed of chemical compounds that are naturally found in human urine and blood, which have been proposed as a possible cancer treatment. While they are still considered experimental, they have been the subject of much discussion and investigation over the past few decades. In this article, we will explore the history of antineoplastons, the results of laboratory, animal, and human studies, and the side effects that have been associated with their use.

A Brief History of Antineoplastons

The idea of using antineoplastons as a cancer treatment was first proposed in 1976 by S.R. Burzynski, MD, PhD. At the time, antineoplastons were isolated from human urine, but over the years, they have been synthesized from readily available chemicals in the developer’s laboratory. According to the developer, antineoplastons are part of a biochemical surveillance system in the body that works as “molecular switches.” They believe that cell differentiation is the key to cancer therapy, and that antineoplastons are the system that directs cancer cells into normal channels of differentiation. People with cancer are said to lack this surveillance system because they do not have an adequate supply of antineoplastons.

One of the theoretical foundations of antineoplaston therapy is the idea of controlling tumor growth through a naturally occurring biochemical mechanism in the body. The developer initially hypothesized the existence of antineoplastons by applying the cybernetic theory of information exchange in autonomous systems to the study of peptides in the blood. They postulated that peptides were the information carriers in the body and that they controlled the transfer of information and the expenditure of energy within the body’s cells. They then began looking for peptides in the blood of cancer patients that might correct abnormal differentiation.

The developer separated and removed the peptides found in human blood, and later discovered that the same peptide fractions existed in human urine. Each peptide fraction was tested in vitro against various normal and neoplastic cell lines to determine its effect on DNA synthesis and growth. The fractions that had little or no inhibitory effect on normal cells but a substantial inhibitory effect on neoplastic cell lines were grouped together and called “antineoplaston A.”

Laboratory, Animal, and Human Studies

To date, no randomized controlled trials showing the effectiveness of antineoplastons have been published in the peer-reviewed scientific literature. However, nonrandomized clinical trials investigating the anticancer efficacy of antineoplastons are underway at the developer’s institute. Despite the lack of randomized controlled trials, laboratory and animal studies have shown some promising results, but more research is needed to determine the true effectiveness of antineoplastons as a cancer treatment.

Side Effects

One of the biggest concerns with antineoplastons is the potential for serious neurologic toxicity. While there have been some reports of side effects, more research is needed to determine the full range of side effects that may be associated with their use. It is important to keep in mind that antineoplastons are not approved by the U.S. Food and Drug Administration for the prevention or treatment of any disease, and their use should be approached with caution.

Conclusion

In conclusion, antineoplastons are an experimental cancer therapy that have been the subject of much investigation over the years. While laboratory and animal studies have shown some promising results, more research is needed to determine their true effectiveness as a cancer treatment. Additionally, the potential for serious side effects and lack of solid clinical evidence from human studies means that antineoplastons should be approached with caution and considered only as part of a comprehensive and well-informed treatment plan. It’s important to consult with a qualified healthcare provider before pursuing this therapy, and to weigh the potential benefits against the risks to make an informed decision.

Source: PDQ Integrative, Alternative, and Complementary

Published online: August 15, 2019.

Therapies Editorial Board. Antineoplastons

Created: November 19, 2007.

(PD0®): Health Professional Version. 2019 Aug

15. In: PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer

Institute (US); 2002-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK65872/

Wait a second. If you want to start writing on Medium yourself and earn money passively you only need a membership for $5 a month. If you sign up with my link https://evanmoon10.medium.com/membership, you support me with a part of your membership fee without additional costs.